Serum levels of soluble CD21 in patients with systemic sclerosis
- First Online:
- 144 Downloads
Systemic sclerosis (SSc) is a systemic disorder that typically results in fibrosis of the skin and multiple internal organ systems. Although the precise mechanism is unknown, overproduction of extracellular matrix proteins, including collagens and fibronectins, and aberrant immune activation might be involved in the pathogenesis. The soluble cluster of differentiation 21 (sCD21) represents the extracellular portion of the CD21 glycoprotein that is released by shedding from the cell surfaces into plasma. sCD21 binds complement fragments and activates monocytes through binding to membrane CD23. The present study was undertaken to investigate the serum levels of sCD21 in patients with SSc. Serum sCD21 levels were reduced with age both in patients with SSc and normal controls. Serum sCD21 levels in patients with SSc were significantly decreased compared to those in control subjects. When we divided patients with SSc into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc), patients with lcSSc had lower levels of serum sCD21 than those with dcSSc. Moreover, the prevalence of pulmonary fibrosis in the patients with dcSSc inversely correlated with serum sCD21 levels. Our finding may support the notion that B-cell activation is involved in the mechanism for pulmonary fibrosis and skin sclerosis.
KeywordsCD21 Enzyme-linked immunosorbent assay Pulmonary fibrosis Systemic sclerosis Limited cutaneous systemic sclerosis
- 5.Nielsen CH, Pedersen ML, Marquart HV, Prodinger WM, Leslie RG (2002) The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells. Eur J Immunol 32:1359–1367PubMedCrossRefGoogle Scholar
- 6.Dempsey PW, Fearon DT (1996) Complement: instructing the acquired immune system through the CD21/CD19 complex. Res Immunol 147(71–75):119–120Google Scholar
- 26.Masilamani M, Rajasekaran N, Singh A, Low H, Albus K, Anders S, Behne F, Eiermann P, Konig K, Mindnich C, Ribarska T, Illges H (2008) Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease. Rheumatol Int 28:1137–1141PubMedCrossRefGoogle Scholar